Four incretin-class research peptides dominate Australian enquiries. This reference compares receptor targets, published half-lives and practical handling for each.
Incretin-class research peptides are no longer a single-compound field. Purity Labs now stocks four materials that Australian labs routinely benchmark against one another, and choosing between them is less about which is 'strongest' and more about which receptor profile answers the question a study is actually asking. This reference sets them side by side.
Receptor targets at a glance
| Compound | Receptor activity described in literature | Reported half-life reference |
|---|---|---|
| Retatrutide | GLP-1 / GIP / glucagon triple agonism | ~6 days |
| Tirzepatide | GLP-1 / GIP dual agonism | ~5 days |
| Semaglutide | GLP-1 mono-agonism | ~7 days |
| Cagrilintide | Amylin / calcitonin receptor agonism | ~7–8 days |
Why the triple agonist changed study design
Retatrutide's addition of glucagon receptor activity to the GLP-1/GIP pairing gives researchers a third signalling axis inside one molecule, which is precisely why comparative work against Tirzepatide has become so common. From a purely practical standpoint it also means a single dose-response experiment can generate three receptor readouts, so material consumption per data point drops — one reason Retatrutide leads the Purity Labs bestseller list.
Handling differences that matter at the bench
- All four are supplied lyophilised and should be brought to room temperature before the vial is opened to avoid condensation on cold powder.
- Reconstitute against the side wall of the vial; never inject diluent directly into the cake and never shake.
- Cagrilintide co-incubation studies typically use separate reconstitutions rather than a shared vial, keeping each concentration independently verifiable.
- Semaglutide's longer published half-life makes it the usual reference compound in stability comparisons.
Choosing a comparator
If a study needs a well-characterised baseline, Semaglutide remains the most heavily published of the four and makes the cleanest control. If the question involves incremental effect from added receptor coverage, the Tirzepatide-to-Retatrutide step is the most informative pairing available today. Cagrilintide sits outside the incretin axis entirely and is most useful as an orthogonal comparator rather than a substitute.
Which of these does Purity Labs stock in Australia?
All four, held as Australian stock with published per-batch HPLC-MS certificates and same-business-day dispatch on cleared payment before 2pm AEST.
Are half-life figures applicable to in-vitro work?
No. The figures above are literature references for the compound class and are included for documentation context only; in-vitro stability depends on your buffer, temperature and handling.
Can I order multiple compounds on one order?
Yes, and bulk pricing applies across the cart automatically rather than per line item.
